Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.68 |
| ▸ | ATR | Q13535 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026996 | 0.94 | PIK3CA (0.68) | PIK3CAATRPIK3CBNAPEPLDPIK3CG | |
| SCHEMBL3264971 | 0.88 | PIK3CA (0.68) | PIK3CAATRPIK3CBNAPEPLDPIK3CG | |
| SCHEMBL1028146 | 0.88 | PIK3CA (0.71) | PIK3CAATRPIK3CBNAPEPLDPIK3CG | |
| SCHEMBL1026999 | 0.88 | PIK3CA (0.65) | PIK3CAPIK3CBNAPEPLDPIK3CGOGA | |
| SCHEMBL3040686 | 0.87 | PIK3CA (0.62) | PIK3CAATRPIK3CBPIK3CG | |
| SCHEMBL13336861 | 0.87 | PIK3CA (0.79) | PIK3CAATRPIK3CBPIK3CGOGA | |
| SCHEMBL1028951 | 0.86 | PIK3CA (0.67) | PIK3CAATRPIK3CBPIK3CGRAF1 | |
| SCHEMBL1028960 | 0.86 | PIK3CA (0.69) | PIK3CAATRPIK3CBNAPEPLDPIK3CG | |
| SCHEMBL1026861 | 0.86 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CGRAF1BRAF | |
| SCHEMBL13336824 | 0.85 | PIK3CA (0.65) | PIK3CAATRPIK3CBNAPEPLDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150546-B1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | claimed |
| EP-2150546-B1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIK3CA, PIP5K1B, PIK3CD | PIK3CA 1/4885ATR 453/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.